Catherine McGuinn
Pediatric Hematology-Oncology · New York, NYNPI 1316194293
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $44,338 of the $67,003 with a category attached, or 66.2%. 8 manufacturers reported payments, led by Genentech USA, Inc. at 55.8% of the total. Reporting peaked in 2024 at $20,846 and has fallen 54.8% since, to $9,416 in 2025. Among pediatric hematology-oncology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 66 payments — averaging $1015.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$37K
- Octapharma USA, Inc.$12K
- CSL Behring$9K
- New York Blood Center, Inc.$3K
- HEMA Biologics, LLC$3K
- Pfizer$2K
- plus $2K from 2 others
Across 98 payments — averaging $4550.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$195K
- Sanofi US Services Inc.$118K
- Takeda Pharmaceuticals U.S.A., Inc.$52K
- Genentech, Inc.$45K
- Spark Therapeutics, Inc.$28K
- Shire North American Group Inc$7K
- plus $2K from 1 others
What the payments were for
- Consulting fees$44,33866%
- Speaking & faculty fees$2,9264%
- Travel & lodging$15,89424%
- Food & beverage$3,0024%
- Education$8321%
- Gifts$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 28 | $37,361 |
| Octapharma USA, Inc. | 7 | $11,549 |
| CSL Behring | 7 | $9,070 |
| New York Blood Center, Inc. | 2 | $2,758 |
| HEMA Biologics, LLC | 6 | $2,515 |
| Pfizer | 5 | $2,158 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $1,426 |
| Shire North American Group Inc | 2 | $166 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HEMLIBRA$36,984
- WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN)$9,767
- HEMGENIX$5,285
- SevenFact$2,500
- NUWIQ$1,675
How this compares
$67,003 in reported general payments places this provider in the 90th percentile of 196 pediatric hematology-oncology providers in New York.
See all pediatric hematology-oncology providers in New York →
Other pediatric hematology-oncology in New York
- Sujit ShethNew York$359K
- Jaap Jan BoelensNew York$303K
- James BusselNew York$204K
- Saara KavianyNew York$144K
- Gary BrittenhamNew York$137K
- James FerraraNew York$118K
- John LevineNew York$98K
- Nai-Kong CheungNew York$86K
- Andrew HarrisNew York$85K
- Joseph OvedNew York$77K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.